NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
23 Jan 2017

Sanifit Announces Enrollment of First Patient in CaLIPSO – a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis

Laboratoris Sanifit S.L., today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472.
18 Jan 2017

Minoryx Therapeutics further strengthens its scientific advisory board

Minoryx Therapeutics today announces that, Dr. Patrick Aubourg, Dr. Marc Engelen, Dr. Florian Eichler and Dr. Gerald Raymond, four renowned clinical experts in X-ALD joined its scientific advisory board.
17 Jan 2017

Aelix Therapeutics appoints industry expert Philippe Monteyne as independent board member

Aelix Therapeutics, has appointed Dr Philippe Monteyne as an independent member of its board of directors.
06 Jan 2017

Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

Kala Pharmaceuticals, Inc. announced today that Mark Iwicki, Chairman and Chief Executive Officer of Kala, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 11, 2017 at 4:00 PM PST.
20 Dec 2016

Takeda makes €10 million equity investment in TiGenix

TiGenix NV announced today that it has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix.
20 Dec 2016

TiGenix announces closing of NASDAQ IPO

TiGenix NV announced today the closing of its initial public offering in the United States totalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS. 
15 Dec 2016

TiGenix raises $35.65 million gross proceeds with NASDAQ IPO

TiGenix NV announced today the pricing of its initial public offering in the United States (the "Offering") totalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares ("ADSs"), representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS. 
15 Dec 2016

Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

Minoryx Therapeutics, today announces that its lead compound MIN-102 has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
05 Dec 2016

TiGenix announces launch of proposed initial public offering in the United States

TiGenix NV announced today that it intends to offer and sell, subject to market and other conditions, 2.75 million American Depositary Shares (“ADSs”) representing 55 million ordinary shares in an initial public offering in the United States (the "Offering").
30 Nov 2016

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

OxThera AB, announces today that it has agreed on a EURO 32 million investment to complete the Oxabact® development program for treatment of Primary hyperoxaluria.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка